A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

2025-523479-49-00 · tracked via the Priya Life Science EU tracker

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Pharmaceutical company

Therapeutic area

Digestive System Diseases

Decision date

22/06/2026

Enrollment target

Sites

Italy, Greece, Netherlands, Poland, Germany, France

Condition studied

Colitis ulcerative

Investigational medicinal product(s)

Placebo for MK-8690MK-8690

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Primary endpoint

Percentage of Participants Achieving Clinical Remission Per Modified Mayo Score (MMS) at Week 12

Endpoint detail

Percentage of Participants With One or More Adverse Events (AEs), Percentage of Participants Who Discontinued Study Intervention Due to an AE, Percentage of Participants Achieving Clinical Response Per MMS at Week 12, Percentage of Participants With Endoscopic Improvement at Week 12, Percentage of Participants Achieving Clinical Remission Per Partial Modified Mayo Score (pMMS) at Week 12, Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement at Week 12

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523479-49-00 on CTIS ↗ ← All trials in the EU